ACE Inhibitors to Prevent End-Stage Renal Disease
Key result
Ramipril decreased the incidence of ESRD by 33% to 100% across tertiles of basal GFR compared to non-ACE inhibitor treatment, with the greatest absolute benefit in patients with the lowest GFR.
Why the study?
Does ramipril reduce the rate of GFR decline and prevent end-stage renal disease in patients with nondiabetic, proteinuric chronic nephropathies?
Population
322 patients with nondiabetic, proteinuric chronic nephropathies and different degrees of renal insufficiency
Comparison
Ramipril vs Non-ACE inhibitor treatment
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Ramipril use was associated with lower ESRD risk across GFR levels; leaves open causal confirmation beyond REIN in prospective cohorts.
Study Design
Type
Observational (n=322)
Structured PICO
Does ramipril reduce the rate of GFR decline and prevent end-stage renal disease in patients with nondiabetic, proteinuric chronic nephropathies?
P
Population
322 patients with nondiabetic, proteinuric chronic nephropathies and different degrees of renal insufficiency
I
Intervention
Ramipril
C
Comparator
Non-ACE inhibitor treatment
O
Outcome
Rate of GFR decline (Delta GFR) and incidence of end-stage renal disease (ESRD)hard clinical
Ramipril provides renoprotection and reduces the risk of ESRD across all degrees of renal insufficiency in nondiabetic proteinuric nephropathy, with maximal benefit when initiated earlier.
Cite This Study
Ruggenenti et al. (2001) conducted an observational in Nondiabetic, proteinuric chronic nephropathies (n=322). Ramipril vs. Non-ACE inhibitor treatment was evaluated on Rate of GFR decline (Delta GFR) and incidence of end-stage renal disease (ESRD). Ramipril decreased the incidence of ESRD by 33% to 100% across tertiles of basal GFR compared to non-ACE inhibitor treatment, with the greatest absolute benefit in patients with the lowest GFR.